Loading...
The first integrase inhibitor approved by the FDA — raltegravir — has ascended to “preferred” status in the U.S. Department of Health and Human Services treatment guidelines. Although it is an excellent twice-daily drug, a similarly effective, once-daily integrase inhibitor would also be welcome. Dolutegravir may well be such a drug, based on 48-week trial results presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention [Van Lunzen J et al. Abstract TUAB0102].
In the phase IIb, industry-sponsored SPRING-1 trial, 205 treatment-naive patients were randomized to receive efavirenz or one of three doses of dolutegravir (10, 25, or 50 mg), each in combination with two investigator-chosen nucleoside reverse transcriptase in…